A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression, addiction and other conditions. In ...
The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament’s natural psilocybin drug candidate PEX010 25mg within palliative care Filament's growing ...
PEX010 is a first-in-class botanical psilocybin drug candidate currently under investigation in 52 clinical trials worldwide for 14 mental health indications "The results of the study demonstrated ...
VANCOUVER, BC, May 8, 2025 /CNW/ - Filament Health Corp. (FH:CA) (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, ...
Benjamin Lightburn, CEO of Filament, is pictured. A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating ...
A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression, addiction and other conditions. In ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A recent boom in psychedelic research has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results